结直肠癌肝转移：机制与治疗
Colorectal cancer liver metastases: mechanism and therapy.
摘要(中文译文)
结直肠癌（CRC）是全球癌症死亡的主要原因之一，肝转移是结直肠癌患者死亡的主要原因。目前结直肠癌肝转移（CRLM）的主要治疗选择包括化疗、放疗、靶向治疗和免疫治疗。然而，CRLM患者的生存率仍低于40%。肝脏独特的免疫耐受微环境近年来被认为是转移定植、免疫逃逸和治疗耐药的核心驱动因素。本综述探讨了CRLM的发生发展，特别关注近期的治疗进展，同时也探讨了有前景的研究方向和新兴治疗策略。对CRLM发病机制和治疗进展的更深入理解将使临床医生能够优化治疗策略并改善患者预后。
Abstract
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide, with liver metastasis representing the principal cause of death in CRC patients. Current primary treatment options for colorectal cancer liver metastases (CRLM) encompass chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, the survival rate for CRLM patients remains below 40%. The unique immune-tolerant microenvironment of the liver has recently been recognized as a central driver of metastatic colonization, immune evasion, and therapeutic resistance. This review examines the development of CRLM, with particular emphasis on recent therapeutic advances. It also explores promising research and emerging treatment strategies. A deeper understanding of CRLM pathogenesis and therapeutic progress will enable clinicians to optimize treatment approaches and improve patient outcomes.
如何引用
AMA
Shan Liu, Liuxian Ban, Wei Zhang, Yutian Sun, Ke Wang, Yuxin Man, et al. Colorectal cancer liver metastases: mechanism and therapy.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1861130.
APA
Shan Liu, Liuxian Ban, Wei Zhang, Yutian Sun, Ke Wang, Yuxin Man, et al (2026). Colorectal cancer liver metastases: mechanism and therapy.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1861130
GB/T 7714
Shan Liu, Liuxian Ban, Wei Zhang, Yutian Sun, Ke Wang, Yuxin Man, et al. Colorectal cancer liver metastases: mechanism and therapy.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1861130.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出